☆ 4.7 Article

Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 38, Issue 15_suppl, Pages 10005-10005

Publisher

American Society of Clinical Oncology (ASCO)

DOI: 10.1200/jco.2020.38.15_suppl.10005

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.